BioSpace News Archive

Dizal (SSE:688192) today announced that the National Medical Products Administration of China has approved golidocitinib for the treatment of adult patients with relapsed or refractory (r/r) peripheral T-Cell lymphoma (PTCL) whose disease has progressed on or were refractory to at least 1 prior systemic therapy.

Redwire Corporation (NYSE: RDW), a leader in space infrastructure for the next generation space economy, announced today that Redwire Chairman and Chief Executive Officer Peter Cannito will present at the Jefferies Virtual Space Summit on June 25, 2024 at 11:40 a.m. EDT.

Woolsey Pharmaceuticals, a clinical-stage drug development company, announced that its investigational drug, CIRARA, was well tolerated and exhibited statistically significant reductions in a key biomarker, Neurofilament Light (NfL), in the REAL Amyotrophic Lateral Sclerosis (ALS) study.

Prime Therapeutics LLC and Magellan Rx Management launched Pharmacy Match, a technology-enabled specialty pharmacy solution designed to drive competition through an expanded specialty pharmacy network and to lower drug costs for plan sponsors.

According to a study published in Nature Communications, research conducted at the Phoenix Children’s Research Institute at the University of Arizona College of Medicine — Phoenix, shows how frequent non-coding FOXF1 gene deletions that interfere with important DNA regulatory regions, called enhancers, can lead to Alveolar Capillary Dysplasia with Misalignment of Pulmonary Veins (ACDMPV), a rare, lethal, genetic lung disease which causes respiratory failure in newborns and infants.

Fortrea (Nasdaq: FTRE), a leading global contract research organization (CRO), today announced that Chief Financial Officer Jill McConnell will participate in a virtual fireside chat hosted by Elizabeth Anderson, senior managing director at Evercore ISI, to discuss Fortrea’s business on Thursday, June 20, 2024 at 2:00 pm ET.

Researchers at the National Institutes of Health (NIH) have developed a non-chemotherapy treatment regimen that is achieving full remissions for some people with aggressive B-cell lymphoma that has come back or is no longer responding to standard treatments.

SMITM CAPITAL MARKETS LTD, has announced a significant agreement with Mid-Atlantic BioTherapeutics, Inc. (MABT), a clinical-stage ready US biopharmaceutical company.